Company profile

Ticker
BIO, BIO.B
Exchange
Website
CEO
Norman D. Schwartz
Employees
Incorporated
Location
Fiscal year end
Former names
BIO RAD LABORATORIES INC
SEC CIK
IRS number
941381833

BIO stock data

(
)

Calendar

30 Oct 20
3 Dec 20
31 Dec 20

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
9 Nov 20 Annette Tumolo Bio-Rad A Common Stock Gift Dispose G No 0 423 0 3,699.348
6 Nov 20 Annette Tumolo Bio-Rad A Common Stock Sell Dispose S No 641.53 246 157.82K 4,122.348
6 Nov 20 Annette Tumolo Bio-Rad A Common Stock Sell Dispose S No 640.78 734 470.33K 4,368.348
6 Nov 20 Annette Tumolo Bio-Rad A Common Stock Sell Dispose S No 639.62 220 140.72K 5,102.348
6 Nov 20 Annette Tumolo Bio-Rad A Common Stock Option exercise Aquire M No 159.32 1,200 191.18K 5,322.348
6 Nov 20 Annette Tumolo NQSO Bio-Rad A Common Stock Option exercise Dispose M No 159.32 1,200 191.18K 600
11 Sep 20 Crowley Michael Bio-Rad A Common Stock Payment of exercise Dispose F No 505.02 298 150.5K 4,043
11 Sep 20 Crowley Michael Bio-Rad A Common Stock Option exercise Aquire M No 0 600 0 4,341
11 Sep 20 Crowley Michael RSU Bio-Rad A Common Stock Option exercise Dispose M No 0 600 0 0
11 Sep 20 Annette Tumolo Bio-Rad A Common Stock Payment of exercise Dispose F No 505.02 298 150.5K 4,122.348
76.7% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 466 460 +1.3%
Opened positions 63 97 -35.1%
Closed positions 57 35 +62.9%
Increased positions 173 158 +9.5%
Reduced positions 170 151 +12.6%
13F shares
Current Prev Q Change
Total value 10.12B 8.55B +18.4%
Total shares 18.99M 19.03M -0.2%
Total puts 29K 23.3K +24.5%
Total calls 17.3K 25K -30.8%
Total put/call ratio 1.7 0.9 +79.9%
Largest owners
Shares Value Change
Vanguard 2.25M $1.16B -2.3%
BLK Blackrock 1.62M $836.19M +2.5%
FMR 1.4M $723.93M +72.1%
STT State Street 958.74K $494.19M +3.4%
American Century Companies 585.82K $301.97M -11.8%
Brown Advisory 465.41K $239.9M +12.1%
IVZ Invesco 459.95K $237.09M +53.9%
WFC Wells Fargo & Co. 414.08K $213.44M -21.7%
Atlanta Capital Management Co L L C 397.97K $205.14M -11.9%
Ubs Global Asset Management Americas 386.14K $199.04M -6.4%
Largest transactions
Shares Bought/sold Change
FMR 1.4M +588.59K +72.1%
IVZ Invesco 459.95K +161.1K +53.9%
Assenagon Asset Management 2.74K -151.83K -98.2%
Aqr Capital Management 235.36K -118.43K -33.5%
WFC Wells Fargo & Co. 414.08K -114.91K -21.7%
GS Goldman Sachs 23.87K -110.35K -82.2%
Hosking Partners 79.39K +79.39K NEW
American Century Companies 585.82K -78.04K -11.8%
Mitsubishi UFJ Trust & Banking 19.48K -71.01K -78.5%
Artemis Investment Management 133.23K -65.03K -32.8%

Financial report summary

?
Risks
  • Changes in the market value of our position in Sartorius AG may materially impact our financial results and might cause us to be deemed an investment company.
  • We may incur losses in future periods due to write-downs in the value of financial instruments.
Management Discussion
  • Percentage sales growth in currency neutral amounts are calculated by translating prior period sales in each local currency using the current period monthly average foreign exchange rates for that currency and comparing that to current period sales.
  • Net sales (sales) for the third quarter of 2020 were $647.3 million compared to $560.6 million in the third quarter of 2019, an increase of 15.5%.  Excluding the impact of foreign currency, third quarter 2020 sales increased by approximately 14.9% compared to the same period in 2019. Currency neutral sales increased in all regions.
  • The Life Science segment sales for the third quarter of 2020 were $324.0 million, an increase of 50.2% compared to the same period last year.  On a currency neutral basis, sales increased 48.8% compared to the third quarter in 2019. The currency neutral sales increase was primarily driven by growth in our PCR, Droplet Digital PCR, and Process Media product lines. A significant portion of the growth in the Life Science segment came from products used to support COVID-19 testing and research. All regions experienced double digit currency neutral sales growth compared to the third quarter of 2019.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: absorption, double, field, headcount, Latin, preference, reinvesting, upcoming, vesting
Removed: bad, began, commenced, commensurate, conducted, consistent, Council, extensive, February, formally, group, innovation, low, machinery, modified, operational, paper, preserved, referendum, stage, tolerance, withdraw